New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...
The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients ...
Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback